# Staar Surgical Co: Form 10-Q for the period ended Sep 30, 2022

- Company: [Staar Surgical Co](/companies/staa.md) (CIK 718937)
- Form: 10-Q
- Filed: 2022-11-02
- Accepted by EDGAR: Nov 2, 2022, 16:11 ET
- Period: 2022-09-30
- Accession: 0001564590-22-036363
- Inline XBRL: yes
- Main document: https://www.sec.gov/Archives/edgar/data/718937/000156459022036363/staa-10q_20220930.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/718937/000156459022036363/

## Figures reported in this filing

Standardized XBRL line items for the period ended 2022-09-30.

| Line item | Period | Value | XBRL concept |
| --- | --- | ---: | --- |
| Revenue | 3 months, 2022-07-02 to 2022-09-30 | $76.0m | us-gaap:Revenues |
| Revenue | 9 months, 2022-01-01 to 2022-09-30 | $220.3m | us-gaap:Revenues |
| Cost of revenue | 3 months, 2022-07-02 to 2022-09-30 | $15.6m | us-gaap:CostOfGoodsAndServicesSold |
| Cost of revenue | 9 months, 2022-01-01 to 2022-09-30 | $46.7m | us-gaap:CostOfGoodsAndServicesSold |
| Gross profit | 3 months, 2022-07-02 to 2022-09-30 | $60.5m | us-gaap:GrossProfit |
| Gross profit | 9 months, 2022-01-01 to 2022-09-30 | $173.6m | us-gaap:GrossProfit |
| Research and development | 3 months, 2022-07-02 to 2022-09-30 | $9.6m | us-gaap:ResearchAndDevelopmentExpense |
| Research and development | 9 months, 2022-01-01 to 2022-09-30 | $26.2m | us-gaap:ResearchAndDevelopmentExpense |
| Selling, general and administrative | 3 months, 2022-07-02 to 2022-09-30 | $46.8m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Selling, general and administrative | 9 months, 2022-01-01 to 2022-09-30 | $130.8m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Operating income | 3 months, 2022-07-02 to 2022-09-30 | $13.7m | us-gaap:OperatingIncomeLoss |
| Operating income | 9 months, 2022-01-01 to 2022-09-30 | $42.8m | us-gaap:OperatingIncomeLoss |
| Income tax | 3 months, 2022-07-02 to 2022-09-30 | $2.3m | us-gaap:IncomeTaxExpenseBenefit |
| Income tax | 9 months, 2022-01-01 to 2022-09-30 | $6.7m | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months, 2022-07-02 to 2022-09-30 | $10.3m | us-gaap:NetIncomeLoss |
| Net income | 9 months, 2022-01-01 to 2022-09-30 | $32.9m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months, 2022-07-02 to 2022-09-30 | $0.21 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 9 months, 2022-01-01 to 2022-09-30 | $0.67 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months, 2022-07-02 to 2022-09-30 | $0.21 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 9 months, 2022-01-01 to 2022-09-30 | $0.69 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months, 2022-07-02 to 2022-09-30 | 49,549,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Diluted shares (weighted) | 9 months, 2022-01-01 to 2022-09-30 | 49,371,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 9 months, 2022-01-01 to 2022-09-30 | $32.7m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 9 months, 2022-01-01 to 2022-09-30 | $14.1m | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Cash and equivalents | at 2022-09-30 | $129.2m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | at 2022-09-30 | $296.9m | us-gaap:AssetsCurrent |
| Total assets | at 2022-09-30 | $394.7m | us-gaap:Assets |
| Current liabilities | at 2022-09-30 | $45.3m | us-gaap:LiabilitiesCurrent |
| Total liabilities | at 2022-09-30 | $74.5m | us-gaap:Liabilities |
| Shareholders' equity | at 2022-09-30 | $320.1m | us-gaap:StockholdersEquity |

## Management's discussion and analysis

As filed, 23,816 characters.

*The matters addressed in this Item 2 that are not historical information constitute “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Readers can recognize forward-looking statements by the use of words like “anticipate,” “estimate,” “expect,” “intend,” “plan,” “believe,” “will,” “should,” “forecast” and similar expressions in connection with any discussion of future operating or financial performance. In particular, these include statements about any of the following: any projections of or guidance as to earnings, revenue, sales, profit margins, expense rate, cash, effective tax rate, product mix, capital expense or any other financial items; the expected impact of the COVID-19 pandemic and related public health measures (including but not limited to their impact on sales, operations or clinical trials globally), the plans, strategies, and objectives of management for future operations or prospects for achieving such plans; statements regarding new, existing, or improved products, including but not limited to, expectations for success of new, existing, and improved products in the U.S. or international markets or government approval of a new or improved products; commercialization of new or improved products; future economic conditions or size of market opportunities; expected costs of operations; statements of belief, including as to achieving 2022 and 2023 business plans; expected regulatory activities and approvals, product launches, and any statements of assumptions underlying any of the foregoing.*

*Although we believe that the expectations reflected in these forward-looking statements are reasonable, such statements are inherently subject to risks and we can give no assurance that our expectations will prove to be correct. Actual results could differ from those described in this report because of numerous factors, many of which are beyond our control. These factors include, without limitation, those described in in our Annual Report on Form 10-K in “Item 1A. Risk Factors” filed on February 23, 2022. We undertake no obligation to update these forward-looking statements after the date of this report to reflect future events or circumstances or to reflect actual outcomes.*

*The following discussion should be read in conjunction with the audited consolidated financial statements of STAAR, including the related notes, provided in this report.*

### Overview

STAAR Surgical Company designs, develops, manufactures, and sells implantable lenses for the eye and companion delivery systems used to deliver the lenses into the eye. We are the world’s leading manufacturer of intraocular lenses for patients seeking refractive vision correction, and we also make lenses for use in surgery to treat cataracts. All the lenses we make are foldable, which allows the surgeon to insert them into the eye through a small incision during minimally invasive surgery. Refractive surgery is performed to treat the type of visual disorders that have traditionally been corrected using eyeglasses or contact lenses. We refer to our lenses used in refractive surgery as “implantable Collamer® lenses” or “ICLs.” The field of refractive surgery includes both lens-based procedures, using products like our ICL family of products, and laser-based procedures like LASIK. Successful refractive surgery can correct common vision disorders such as myopia, hyperopia, and astigmatism. Cataract surgery is a common outpatient procedure where the eye’s natural lens that has become cloudy with age is removed and replaced with an artificial lens called an intraocular lens (“IOL”) to restore the patient’s vision. STAAR employs a commercialization strategy that strives for sustainable profitable growth. Our goal is to position our refractive lenses throughout the world as primary and premium solutions for patients seeking visual freedom from wearing eyeglasses or contact lenses while achieving excellent visual acuity through refractive vision correction. We position our cataract IOL lenses used in surgery that treats cataracts based on quality and value.

### Recent Developments

STAAR achieved 30% net sales growth in the third quarter despite constant currency challenges and, in Europe, macroeconomic headwinds. In the third quarter global ICL unit growth was up 40% year over year, highlighted by unit growth in China up 52%, the U.S. up 63%, Japan up 40%, South Korea up 49% and Asia Pacific distributor markets up 47%. We advanced our patient awareness, engagement and market building initiatives for EVO in the U.S. during and subsequent to the third quarter, and introduced our presbyopia lens, EVO Viva™, to surgeons at our Experts Meeting preceding the annual congress of the European Society of Cataract and Refractive Surgeons. In China, we expect to exceed a 25% share of refractive surgery market units by year end. Due to tighter COVID restrictions in China resulting in expected delayed demand in the fourth quarter, ongoing headwinds in Europe, weakness in the Yen and Euro, and lower Other Products sales, we now anticipate total net sales will be approximately $285 million for fiscal 2022. Our fiscal 2022 outlook includes ICL sales of approximately $272 million, representing 28% year over year growth, and Other Products sales of approximately $13 million.”

Our low margin Other Products business, which represents approximately 5% of sales and consists of cataract IOLs, IOL injectors and injector parts, has faced increasing supply chain challenges. As a result of third-party materials and supply chain challenges that only affect our Other Products business, we will no longer be able to support Other Products as we have historically. We will continue to support customers of Other Products through the end of 2023. As we look to fiscal 2023, we expect to achieve approximately 30% ICL sales growth, year over year, to approximately $355 million in total company net sales which contemplates limited sales from Other Products. We do not expect contribution from Other Products thereafter. We continue to see significant growth potential for our EVO family of lenses globally.

### Critical Accounting Estimates

This Management’s Discussion and Analysis of Financial Condition and Results of Income discusses and analyzes data in our unaudited Condensed Consolidated Financial Statements provided in this report, which we have prepared in accordance with U.S. generally accepted accounting principles. Preparation of these financial statements requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenue and expenses, and related disclosure of contingent assets and liabilities. Management bases its estimates on historical experience and on various other assumptions that it believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Senior management has discussed the development, selection and disclosure of these estimates with the Audit Committee of our Board of Directors. Actual conditions may differ from our assumptions and actual results may differ from our estimates.

Management believes that there have been no significant changes during the nine months ended September 30, 2022 to the items that we disclosed as our critical accounting estimates in Management’s Discussion and Analysis of Financial Condition and Results of Operations in our Annual Report on Form 10-K for the fiscal year ended December 31, 2021.

### Results of Operations

The following table shows the percentage of our total sales represented by certain items reflected in our Condensed Consolidated Statements of Income for the periods indicated.

|  | Percentage of Net Sales for Three Months September 30, 2022 | October 1, 2021 | Percentage of Net Sales for Nine Months September 30, 2022 | October 1, 2021 |
| --- | ---: | ---: | ---: | ---: |
| Net sales | 100.0% | 100.0% | 100.0% | 100.0% |
| Cost of sales | 20.5% | 22.4% | 21.2% | 22.1% |
| Gross profit | 79.5% | 77.6% | 78.8% | 77.9% |
| General and administrative | 18.4% | 18.9% | 18.1% | 19.0% |
| Selling and marketing | 30.4% | 31.1% | 29.3% | 29.3% |
| Research and development | 12.7% | 14.2% | 12.0% | 14.5% |
| Total selling, general and administrative | 61.5% | 64.2% | 59.4% | 62.8% |
| Operating income | 18.0% | 13.4% | 19.4% | 15.1% |
| Total other expense, net | (1.5)% | (0.8)% | (1.5)% | (0.9)% |
| Income before income taxes | 16.5% | 12.6% | 17.9% | 14.2% |
| Provision for income taxes | 3.0% | 2.3% | 3.0% | 2.8% |
| Net income | 13.5% | 10.3% | 14.9% | 11.4% |

19

### Net Sales

The following table presents our net sales, by product (dollars in thousands):

|  | Three Months Ended September 30, 2022 | October 1, 2021 | Percentage Change 2022 vs. 2021 | Nine Months Ended September 30, 2022 | October 1, 2021 | Percentage Change 2022 vs. 2021 |
| --- | ---: | ---: | ---: | ---: | ---: | ---: |
| ICLs | $71,953 | $54,153 | 32.9% | $208,550 | $159,889 | 30.4% |
| Other product sales: |  |  |  |  |  |  |
| Cataract IOLs | 2,191 | 2,525 | (13.2)% | 7,640 | 9,324 | (18.1)% |
| Other surgical products | 1,902 | 1,674 | 13.6% | 4,157 | 2,258 | 84.1% |
| Total other product sales | 4,093 | 4,199 | (2.5)% | 11,797 | 11,582 | 1.9% |
| Net sales | $76,046 | $58,352 | 30.3% | $220,347 | $171,471 | 28.5% |

Net sales for the three months ended September 30, 2022 increased 30% from the same period of 2021. The increase in net sales was due to increased ICL sales of $17.8 million. Changes in foreign currency unfavorably impacted net sales by $4.0 million.

Net sales for the nine months ended September 30, 2022 increased 29% from same period of 2021. The increase in net sales was due to increased ICL sales of $48.7 million. Changes in foreign currency unfavorably impacted net sales by $9.0 million.

Total ICL sales for the three months ended September 30, 2022 increased 33% from the same period of 2021, with unit increase of 40%. The APAC region sales increased by 40%, with unit growth up 47%, due to sales growth in Korea up 50%, China up 49%, other APAC regions up 49% and Japan up 12%. The Europe, Middle East, Africa and Latin America region sales decreased 9% with unit decrease of 2%, due to sales decreases in in our direct markets down 12% and distributor markets down 4%. The North America region sales increased 66%, with unit growth up 56%, primarily due to sales growth in the U.S. up 75%. In late March 2022, the U.S. started to sell EVO ICLs. Changes in foreign currency unfavorably impacted ICL sales by $3.2 million for the three months ended September 30, 2022, which impacted our Japan and Europe, Middle East and Africa markets. ICL sales represented 94.6% and 92.8% of our total sales for the three months ended September 30, 2022 and October 1, 2021, respectively.

Total ICL sales for the nine months ended September 30, 2022 increased 30% from the same period of 2021, with unit increase of 38%. The APAC region sales increased by 38%, with unit growth up 43%, due to sales growth in other APAC regions up 59%, India up 44%, China up 44%, Korea up 25% and Japan up 16%. The Europe, Middle East, Africa and Latin America region sales decreased 1% with unit growth up 12%, due to sales decreases in our direct markets down 8%, offset by sales growth in distributor markets up 8%. The North America region sales increased 43%, with unit growth up 35%, primarily due to sales growth in the U.S. up 47%. In late March 2022, the U.S. started to sell EVO ICLs. Changes in foreign currency unfavorably impacted ICL sales by $7.2 million for the nine months ended September 30, 2022, which impacted our Japan and Europe, Middle East and Africa markets. ICL sales represented 94.6% and 93.2% of our total sales for the nine months ended September 30, 2022 and October 1, 2021, respectively.

Other product sales, including cataract IOLs for the three months ended September 30, 2022, decreased 3% from the same period of 2021, due to decreased sales of cataract IOLs, partially offset by other surgical products. Other product sales for the nine months ended September 30, 2022, increased 2% due to other surgical products, offset by decreased sales of cataract IOLs. Included in other product sales are sales of preloaded injector parts. In the first half of 2021, we experienced product yield issues requiring rework related to preloaded injector parts manufactured on our behalf by a third-party vendor then sold by us to a third-party manufacturer for product they sell to their customers. Changes in foreign currency unfavorably impacted other product sales by $0.8 million and $1.8 million for the three and nine months September 30, 2022, respectively. Other product sales represented 5.4% and 7.2% of our total sales for the three months ended September 30, 2022 and October 1, 2021, respectively, and represented 5.4% and 6.8% of our total sales for the nine months ended September 30, 2022 and October 1, 2021, respectively.

### Gross Profit

The following table presents our gross profit and gross profit margin (dollars in thousands):

|  | Three Months Ended September 30, 2022 | October 1, 2021 | Percentage Change 2022 vs. 2021 | Nine Months Ended September 30, 2022 | October 1, 2021 | Percentage Change 2022 vs. 2021 |
| --- | ---: | ---: | ---: | ---: | ---: | ---: |
| Gross profit | $60,462 | $45,301 | 33.5% | $173,598 | $133,646 | 29.9% |
| Gross margin | 79.5% | 77.6% |  | 78.8% | 77.9% |  |

Gross profit for the three months ended September 30, 2022 increased 33.5% from the same period of 2021. Gross profit margin increased to 79.5% of revenue for the three months ended September 30, 2022 compared to 77.6% of revenue for the three months ended October 1, 2021, due mainly to product and geographic sales mix, partially offset by increased period costs associated with manufacturing projects.

Gross profit for the nine months ended September 30, 2022 increased 29.9% from the same period of 2021. Gross profit margin increased to 78.8% of revenue for the nine months ended September 30, 2022 compared to 77.9% of revenue for the nine months ended October 1, 2021, due mainly to product and geographic sales mix, partially offset by inventory reserves recognized as a result of discontinuance of our older generation Visian ICL in the U.S. and increased period costs associated with manufacturing projects.

### General and Administrative Expense

The following table presents our general and administrative expenses (dollars in thousands):

|  | Three Months Ended September 30, 2022 | October 1, 2021 | Percentage Change 2022 vs. 2021 | Nine Months Ended September 30, 2022 | October 1, 2021 | Percentage Change 2022 vs. 2021 |
| --- | ---: | ---: | ---: | ---: | ---: | ---: |
| General and administrative expense | $14,011 | $11,018 | 27.2% | $39,934 | $32,671 | 22.2% |
| Percentage of sales | 18.4% | 18.9% |  | 18.1% | 19.0% |  |

General and administrative expenses for the three months ended September 30, 2022 increased 27.2% from the same period of 2021 due to increased stock-based compensation expenses, facility costs and outside services. General and administrative expenses for the nine months ended September 30, 2022 increased 22.2% from the same period of 2021 due to increased facility costs, stock-based compensation expenses and outside services.

### Selling and Marketing Expense

The following table presents our selling and marketing expenses (dollars in thousands):

|  | Three Months Ended September 30, 2022 | October 1, 2021 | Percentage Change 2022 vs. 2021 | Nine Months Ended September 30, 2022 | October 1, 2021 | Percentage Change 2022 vs. 2021 |
| --- | ---: | ---: | ---: | ---: | ---: | ---: |
| Selling and marketing expense | $23,130 | $18,175 | 27.3% | $64,633 | $50,229 | 28.7% |
| Percentage of sales | 30.4% | 31.1% |  | 29.3% | 29.3% |  |

Selling and marketing expenses for the three months ended September 30, 2022 increased 27.3% from the same period of 2021 due to increased trade shows and sales meetings, advertising and promotional activities, travel expenses and stock-based compensation expenses. Selling and marketing expenses for the nine months ended September 30, 2022 increased 28.7% from the same period of 2021 due to increased advertising and promotional activities, trade shows and sales meetings, travel expenses and stock-based compensation expenses.

### Research and Development Expense

The following table presents our research and development expenses (dollars in thousands):

|  | Three Months Ended September 30, 2022 | October 1, 2021 | Percentage Change 2022 vs. 2021 | Nine Months Ended September 30, 2022 | October 1, 2021 | Percentage Change 2022 vs. 2021 |
| --- | ---: | ---: | ---: | ---: | ---: | ---: |
| Research and development expense | $9,616 | $8,271 | 16.3% | $26,193 | $24,790 | 5.7% |
| Percentage of sales | 12.7% | 14.2% |  | 12.0% | 14.5% |  |

Research and development expenses for the three months ended September 30, 2022 increased 16.3% from the same period of 2021 due mainly to increased salary-related and payroll tax expenses. Research and development expenses for the nine months ended September 30, 2022 increased 5.7% from the same period of 2021 due mainly to increased salary-related and payroll tax expenses and stock-based compensation expenses, partially offset by decreased clinical expenses associated with our clinical trials.

### Other Expense, Net

The following table presents our other expenses, net (dollars in thousands):

|  | Three Months Ended September 30, 2022 | October 1, 2021 | Percentage Change 2022 vs. 2021 | Nine Months Ended September 30, 2022 | October 1, 2021 | Percentage Change 2022 vs. 2021 |
| --- | ---: | ---: | --- | ---: | ---: | --- |
| Other expense, net | $(1,128) | $(461) | —\* | $(3,265) | $(1,626) | —\* |
| Percentage of sales | (1.5)% | (0.8)% |  | (1.5)% | (0.9)% |  |

\* Denotes change is greater than +100%.

The change in other expense, net for the three and nine months ended September 30, 2022 and October 1, 2021, respectively, was due primarily to foreign exchange losses (primarily euro), and for the three and nine months ended September 30, 2022, partially offset by increased interest income mainly due to our investments held available for sale.

### Income Taxes

The following table presents our income tax provision (dollars in thousands):

|  | Three Months Ended September 30, 2022 | October 1, 2021 | Percentage Change 2022 vs. 2021 | Nine Months Ended September 30, 2022 | October 1, 2021 | Percentage Change 2022 vs. 2021 |
| --- | ---: | ---: | ---: | ---: | ---: | ---: |
| Income tax provision | $2,315 | $1,356 | 70.7% | $6,671 | $4,751 | 40.4% |

The effective tax rates for the three months ended September 30, 2022 and October 1, 2021 was 18.4% and 18.4%, respectively, and was 16.9% and 19.5%, for the nine months ended September 30, 2022 and October 1, 2021, respectively. Our effective tax rates differ from the U.S. federal statutory rate of 21% for the three and nine months ended September 30, 2022 and October 1, 2021, respectively, primarily due to the income taxes generated in foreign jurisdictions. The differences in the effective tax rate for the three and nine months ended September 30, 2022 compared to the same period in 2021 was primarily due to jurisdictions in which the income is earned.

Our future effective income tax rate depends on various factors, such as changes in tax laws, regulations, accounting principles, or interpretations thereof, and the geographic composition of our pre-tax income. We carefully monitor these factors and adjust our effective income tax rate accordingly.

### Liquidity and Capital Resources

We believe that current cash and cash equivalents, investments available for sale and future cash flow from operating activities will be sufficient to meet our anticipated cash needs, including working capital needs, capital expenditures and contractual obligations for at least 12 months from the issuance date of the financial statements included in this quarterly report. Our financial condition at September 30, 2022 and December 31, 2021 included the following (in thousands):

|  | September 30, 2022 | December 31, 2021 | 2022 vs. 2021 |
| --- | ---: | ---: | ---: |
| Cash and cash equivalents | $129,242 | $199,706 | $(70,464) |
| Investments available for sale | 95,451 | — | 95,451 |
| Total | $224,693 | $199,706 | $24,987 |
| Current assets | $296,910 | $271,411 | $25,499 |
| Current liabilities | 45,320 | 48,802 | (3,482) |
| Working capital | $251,590 | $222,609 | $28,981 |

Cash and cash equivalents include cash and balances in deposits and money market accounts held at banks and financial institutions. Our investment policy primary objective is capital preservation while maximizing our return on investment. Investments available for sale may include U.S. government and corporate debt securities, commercial paper, certain certificates deposit and related security types, that are rated by two nationally recognized statistical rating organizations with minimum investment grade ratings of AAA to A-/A-1+ to A-2, or the equivalent. There are also limits to the amount of credit exposure in any given security type. We do not have any off-balance sheet arrangements.

A summary of cash flows for the nine months ended September 30, 2022 and October 1, 2021 was as follows (in thousands):

| Cash flows from: | Nine Months Ended September 30, 2022 | October 1, 2021 |
| --- | ---: | ---: |
| Operating activities | $32,745 | $35,464 |
| Investing activities | (109,659) | (8,956) |
| Financing activities | 8,095 | 18,009 |
| Effect of exchange rate changes | (1,645) | (724) |
| Net increase (decrease) in cash and cash equivalents | (70,464) | 43,793 |
| Cash and cash equivalents, at beginning of year | 199,706 | 152,453 |
| Cash and cash equivalents, at end of year | $129,242 | $196,246 |

For the nine months ended September 30, 2022, net cash used by operating activities consisted of $32.9 million in net income, $20.6 million in non-cash items, offset by $20.8 million in working-capital changes.

In the three months ended September 30, 2022, we decided to invest our cash in slightly higher yielding securities. For the nine months ended September 30, 2022, net cash used in investment activities was $109.7 million which consisted of $95.6 million in purchases of investments available for sale and $14.1 million in purchases of property, plant and equipment. The increase in investments of property, plant and equipment of $5.1 million for the nine months ended September 30, 2022 relative to the same period of 2021, was due to increased investments in manufacturing facilities.

Net cash provided by financing activities for the nine months ended September 30, 2022 consisted of $8.2 million of proceeds from the exercise of stock options. For the nine months ended October 1, 2021, net cash provided by financing activities consisted of $18.3 million of proceeds from the exercise of stock options, partially offset by $0.3 million repayment of finance lease obligations.

### Commitments

#### Employment Agreements

The Company’s Chief Executive Officer entered into an employment agreement with the Company, effective March 1, 2015. She and certain officers have as provisions of their agreements certain rights, including continuance of cash compensation and benefits, upon a “change in control,” which may include an acquisition of substantially all of its assets, or termination “without cause or for good reason” as defined in the employment agreements.

## Market risk

As filed, 245 characters.

During the nine months ended September 30, 2022, there have been no material changes in the Company’s qualitative and quantitative market risk since the disclosure in the Company’s Annual Report on Form 10-K for the year ended December 31, 2021.

## Controls and procedures

As filed, 3,366 characters.

### Disclosure Controls and Procedures

As of the end of the period covered by this report, we carried out an evaluation, under the supervision and with the participation of our management, including our CEO and CFO, of the effectiveness of the design and operation of the disclosure controls and procedures of the Company. Based on that evaluation, our CEO and CFO concluded, as of the end of the period covered by this quarterly report on Form 10-Q, that our disclosure controls and procedures were effective. For purposes of this statement, the term “disclosure controls and procedures” means controls and other procedures of the Company that are designed to ensure that information required to be disclosed by the Company in the reports that it files or submits under the Securities Exchange Act (15 U.S.C. 78a et seq.) is recorded, processed, summarized and reported, within the time periods specified in the Securities and Exchange Commission’s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by the Company in the reports that it files or submits under the Act is accumulated and communicated to the Company’s management, including its principal executive and principal financial officers, or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure.

Our management, including the CEO and the CFO, do not expect that our disclosure controls and procedures or our internal control over financial reporting will necessarily prevent all fraud or material errors. An internal control system, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. Further, the design of a control system must reflect the fact that there are resource constraints, and the benefits of controls must be considered relative to their costs. Because of the inherent limitations on all internal control systems, our internal control system can provide only reasonable assurance of achieving its objectives and no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, within our Company have been detected. These inherent limitations include the realities that judgments in decision-making can be faulty, and that breakdowns can occur because of simple error or mistake. Additionally, controls can be circumvented by the individual acts of some persons, by collusion of two or more people, or by management override of the control. The design of any system of internal control is also based in part upon certain assumptions about the likelihood of future events, and can provide only reasonable, not absolute, assurance that any design will succeed in achieving its stated goals under all potential future conditions. Over time, controls may become inadequate because of changes in circumstances, or the degree of compliance with the policies and procedures may deteriorate.

### Changes in Internal Control over Financial Reporting

There were no changes in our internal control over financial reporting during the quarter ended September 30, 2022 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

## Risk factors

As filed, 452 characters.

Our short and long-term success is subject to many factors that are beyond our control. Investors and prospective investors should consider carefully information contained in this report and the risks and uncertainties described in “Part I—Item 1A—Risk Factors” of the Company’s Form 10-K for the fiscal year ended December 31, 2021. Such risks and uncertainties could materially adversely affect our business, financial condition or operating results.

Filed Nov 2, 2022.
Source: SEC EDGAR, the filing index for accession 0001564590-22-036363. Last ingested by Listed: Nov 4, 2026, 17:00 ET. No prices; not investment advice.
